Preventing Venous Thromboembolism During Hematologic Cancer Care

Abstract

Venous thromboembolism (VTE) is a significant and potentially life-threatening complication in patients undergoing care for hematologic malignancies. This review examines the epidemiology, pathophysiology, risk factors, clinical features, diagnostic pathways, and management strategies for VTE in this patient population. Emphasis is placed on evidence-based prevention, recent advancements, and current guideline recommendations for optimizing patient outcomes while balancing bleeding risk. The review synthesizes recent clinical data and expert consensus to provide actionable insights for practicing hematologists and oncologists.

Introduction

Hematologic cancers, including leukemia, lymphoma, and multiple myeloma, are frequently complicated by thrombotic events, with venous thromboembolism (VTE) representing a major cause of morbidity and mortality. The intersection of cancer-related hypercoagulability, intensive treatment regimens, and patient-specific vulnerabilities underscores the need for a nuanced approach to VTE prevention. Timely identification of at-risk individuals and implementation of targeted prophylactic strategies are critical to improving clinical outcomes.

Epidemiology / Disease Burden

VTE incidence in hematologic malignancies is notably higher than in the general population, with reported rates ranging from 3% to 20%, depending on the cancer subtype and treatment modalities. Multiple myeloma patients receiving immunomodulatory drugs face especially elevated risks, with cumulative incidences approaching 15% in some cohorts. VTE not only contributes to short-term morbidity but also negatively impacts long-term survival, increases hospitalizations, and complicates therapeutic decision-making. These epidemiological trends highlight the necessity for vigilant prevention efforts throughout the continuum of hematologic cancer care.

Pathophysiology

The pathogenesis of VTE in hematologic cancer involves a multifactorial interplay of cancer-induced hypercoagulability, endothelial injury, and stasis—elements of Virchow’s triad. Tumor cells can directly activate coagulation via tissue factor expression and the release of procoagulant microparticles. Concurrently, chemotherapy, central venous catheters, infections, and immobility exacerbate endothelial dysfunction and venous stasis. Distinct hematologic malignancies may introduce unique thrombotic risks, such as increased viscosity in polycythemia vera or prothrombotic immunoglobulins in multiple myeloma. Understanding these mechanisms is essential for individualized risk assessment and prevention planning.

Risk Factors

Major risk factors for VTE in hematologic malignancies include advanced disease stage, older age, prior thrombotic events, active chemotherapy (especially regimens containing thalidomide, lenalidomide, or high-dose steroids), obesity, prolonged immobility, and the presence of central venous catheters. Disease-specific factors such as high tumor burden, leukocytosis, and the use of erythropoiesis-stimulating agents further compound risk. Recent studies have identified genetic thrombophilias and elevated D-dimer as additional contributors. Recognizing these variables enables clinicians to stratify patients and tailor prophylactic interventions.

Clinical Features

VTE in hematologic cancer often presents with non-specific symptoms—swelling, pain, erythema, or functional impairment of an affected limb in cases of deep vein thrombosis (DVT), or chest pain, dyspnea, and hypoxemia in pulmonary embolism (PE). However, atypical venous sites such as the splanchnic or cerebral veins can be involved, particularly in patients with myeloproliferative neoplasms. High clinical suspicion is warranted, especially in patients with unexplained respiratory or neurological symptoms during active treatment.

Diagnosis

Timely and accurate diagnosis of VTE requires a systematic approach integrating clinical assessment, risk stratification tools, and imaging. While D-dimer is sensitive, its specificity is limited in cancer patients due to frequent background elevations. Compression ultrasonography is first-line for suspected DVT, while CT pulmonary angiography is the gold standard for PE diagnosis. In select scenarios, MRI or venography may be utilized, especially for atypical thromboses. Clinical decision rules such as the Khorana score aid in risk prediction but have limitations in hematologic malignancies, necessitating individualized clinical judgment.

Treatment & Management

Anticoagulation remains the cornerstone of VTE management, with low molecular weight heparins (LMWH) traditionally preferred due to robust evidence in cancer-associated thrombosis. Recent trials have demonstrated the non-inferiority of direct oral anticoagulants (DOACs) such as apixaban and rivaroxaban, though their use requires careful consideration of bleeding risk, renal function, and potential drug-drug interactions with chemotherapy agents. Duration of therapy is typically at least 3–6 months, or as long as active cancer persists. In cases of contraindications or high bleeding risk, mechanical prophylaxis and inferior vena cava filters may be considered, though these are reserved for select scenarios.

Recent Advances / Emerging Therapies

Recent advances include the validation of DOACs in cancer-associated VTE, supported by trials such as Hokusai-VTE Cancer and SELECT-D. Ongoing research is investigating individualized risk-adapted prophylaxis using biomarkers and clinical algorithms. Novel anticoagulants with improved safety profiles, such as factor XI inhibitors, are under investigation. Personalized medicine approaches leveraging genetic and molecular data may soon refine risk stratification and prophylaxis decisions, potentially transforming the prevention landscape in hematologic oncology.

Guideline Recommendations

International guidelines, including those from the American Society of Clinical Oncology (ASCO), International Society on Thrombosis and Haemostasis (ISTH), and National Comprehensive Cancer Network (NCCN), recommend risk-adapted prophylaxis for patients with hematologic malignancies. Pharmacologic prophylaxis with LMWH or DOACs is advised for hospitalized, high-risk, or ambulatory patients receiving thrombogenic therapies, provided bleeding risk is acceptable. Routine prophylaxis in all outpatients is not universally endorsed due to variable risk profiles. Regular reassessment of VTE and bleeding risk, multidisciplinary collaboration, and patient education are emphasized as best practices.

Conclusion

Preventing venous thromboembolism during hematologic cancer care demands a comprehensive, evidence-based, and patient-centered approach. Recent advances in risk stratification, pharmacologic options, and emerging therapies are reshaping prophylactic strategies and offer hope for improved outcomes. Clinicians must remain vigilant, applying guideline-informed interventions tailored to individual patient profiles, while balancing thrombotic and hemorrhagic risks. Ongoing research and clinical innovation will continue to refine prevention paradigms and reduce the burden of VTE in this vulnerable population.